The system was evaluated on test subjects within a sound-proof booth, a noisy hospital ward, and within their homes. The system includes a wireless cellular modem capable of notifying a remote healthcare professional in the event that a significant change in hearing has occurred in the patient. This paper describes the design of a technology, the ototoxicity identification (OtoID), that includes a portable audiometer with HF test functionality that meets ANSI/ASA S3.6-2010 standards and is capable of reliably detecting a person's drug-related hearing changes relative to a baseline period (i.e., before ototoxic drugs) using an automated test. A portable audiometer is currently not available that is 1) capable of automatic or manual (by an audiologist) operation 2) designed with precision pure-tone functionality up to 20 kHz and 3) able to remotely transfer health status information to a healthcare professional. Patients could monitor their own hearing using a device that alerts healthcare professionals in the event of a change in hearing. Telehealth technology may improve access to ototoxicity monitoring. Once ototoxicity is detected, the oncology medical team could adjust the drug dosage or switch to medications that are less ototoxic. Monitoring of HF hearing loss can be an effective means for early detection of ototoxicity caused by chemotherapy.

Damage typically occurs first in the more basal regions of the cochlea which are specific for high-frequency (HF) hearing and progresses to more apical regions that are relevant to speech understanding.

Drugs such as cisplatin can cause permanent damage to hearing if not detected early. Cancer treatment often requires patients to be exposed to drugs that can damage hearing.

Home audiometer hearing test download